2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1
1
Status
Recruiting
2
Active not recruiting
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
NET
3
Endocrine
3
Sarcoma
1
Lymphoid
1
Gastrointestinal
1
CNS
1
Conditions
Neuroendocrine Tumors
3
Thymus Neoplasms
1
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Central Nervous System Neoplasms
1
Interventions
Specimen Handling
655
pembrolizumab
608
Magnetic Resonance Spectroscopy
561
Carboplatin
449
Cisplatin
398
Cyclophosphamide
396
Biopsy
380
Nivolumab
325
Paclitaxel
323
Gemcitabine
317
Radiotherapy
298
Bevacizumab
248
Dexamethasone
223
fludarabine
215
Docetaxel
202
durvalumab
195
Oxaliplatin
189
venetoclax
186
atezolizumab
183
Fluorouracil
177
Rituximab
176
Pemetrexed
173
Capecitabine
170
Radiation
168
Doxorubicin
166
Radiosurgery
161
Ipilimumab
147
Etoposide
142
Leucovorin
140
Lenalidomide
139
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
90 days
×
Clear all
NCT05918302
2026-05-12
LEVEL
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
Recruiting
170 enrolled
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled
NCT03049189
2026-04-06
COMPETE
ITM Solucin GmbH
Phase 3
Active not recruiting
324 enrolled
15 charts